Domainex announces the release of its latest generation LeadBuilder
virtual screening platform.
Cambridge, UK, 29 October 2009.
Domainex Ltd has released the next generation of its LeadBuilder virtual
screening technology. LeadBuilder is the proprietary lead generation platform
developed by Domainex to provide unusually rapid and cost-effective access
to high-quality small-molecule drug leads, particularly against novel or difficult
target proteins. As such, it is well-suited to the needs of both university groups
engaged in Translational Research and to emerging biotechnology and
LeadBuilder employs proprietary search methods to interrogate a vast
database of commercially-available compounds with target-specific queries.
These queries are defined by using protein or ligand derived information - or
ideally by combining knowledge from both of these sources. The latest
enhancements to LeadBuilder include an expanded database of over six
million commercial compounds, and the incorporation of a number of software
upgrades. Compounds which Domainex selects using LeadBuilder are
purchased and tested in biochemical assays to give hit rates which are
typically between 1-10%: i.e. three orders of magnitude better than random,
high-throughput screening (HTS). Critically, in contrast to HTS, LeadBuilder
compounds make “ideal” screening hits, as they are rich in pharmacophoric
features and possess favourable molecular properties combined with
predictions of excellent ADME and toxicity profiles.
Dr Trevor Perrior, Research Director of Domainex, commented: “It is generally
agreed that one of the most influential factors in determining whether or not a
drug research project will be successful is the quality of the starting point,
which is usually a screening hit. By using LeadBuilder, we can make high-
quality hits available to everyone without them needing to make an investment
in the time and expense of high-throughput screening. The latest generation
LeadBuilder has been successfully validated on several targets - both for
clients such as Breakthrough Breast Cancer, and for Domainex’s internal
pipeline - and we look forward to working with this powerful technology on our
customers’ drug discovery projects”.
- ENDS -
• Domainex uses unique and proprietary technologies to resolve
common bottlenecks facing the pharmaceutical and biotechnology
industries in the post-genomic era. Major discovery 'gaps' exist
between the vast amount of genomic information that is now available,
the accessibility of the corresponding proteins for use in target
validation and drug discovery, and the identification of robust hits in a
cost effective manner. Founded in 2002, Domainex is a privately
owned company with laboratories in Cambridge, England, and offices
in the London Bioscience Innovation Centre.
• Domainex has developed a number of platform technologies
specifically aimed at enabling biotech or university groups who have
exciting new drug targets. Its Combinatorial Domain Hunting (CDH)
technology will deliver protein constructs that are soluble, stable, and
produced in high-yield - thereby opening up the path to high throughput
screening, structural biology, or antibody production. Domainex has
also developed LeadBuilder - a virtual screening approach for targets
which is specifically aimed at identifying hit molecules that are ideally
suited for further development. The experienced medicinal chemistry
team has a proven track record in supporting biotech or university
groups by providing expertise to take hit compounds through lead
optimisation and on to candidate selection. Several compounds arising
from these collaborations are currently in clinical evaluation.
• Domainex works with clients on a fee-for-service basis. In 2008, the
company secured investment to establish its own internal drug
discovery pipeline based upon a number of targets in oncology. These
targets are being progressed using Domainex’s platform technologies.
• For more information see: www.domainex.co.uk .
For further information, please contact:
Dr Eddy Littler +44 (0) 1223 433186
Tristan Jervis +44 (0) 207 861 3838
De Facto Communications E-mail : firstname.lastname@example.org